Found: 9
Select item for more details and to access through your institution.
Design and Implementation of a Brief, Self-Directed Course on Immunotherapy Best Practices for Neurology Trainees.
- Published in:
- Journal of Medical Education & Curricular Development, 2024, p. 1, doi. 10.1177/23821205241271546
- By:
- Publication type:
- Article
Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2024, p. 1, doi. 10.1177/17562864241233858
- By:
- Publication type:
- Article
A cross‐sectional natural history study of aspartylglucosaminuria.
- Published in:
- Journal of Inherited Metabolic Disease Reports, 2022, v. 63, n. 5, p. 425, doi. 10.1002/jmd2.12294
- By:
- Publication type:
- Article
Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2017, v. 74, n. 5, p. 574, doi. 10.1001/jamaneurol.2016.5131
- By:
- Publication type:
- Article
A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis.
- Published in:
- Therapeutic Advances in Chronic Disease, 2023, p. 1, doi. 10.1177/20406223231202645
- By:
- Publication type:
- Article
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
- Published in:
- Journal of Nanobiotechnology, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12951-023-02236-z
- By:
- Publication type:
- Article
Eine Übersicht über neuro-ophthalmologische Erkrankungen bei Afroamerikanern und Hispanics mit multipler Sklerose.
- Published in:
- Kompass Ophthalmologie, 2024, v. 10, n. 1, p. 4, doi. 10.1159/000535291
- By:
- Publication type:
- Article
The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives.
- Published in:
- Journal of Central Nervous System Disease, 2022, p. 1, doi. 10.1177/11795735221123911
- By:
- Publication type:
- Article